Switch theme
Sign up to access all valuation multiples
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
1997
184
LTM Revenue $86.1M
LTM EBITDA -$13.9M
$440M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
NeuroPace has a last 12-month revenue (LTM) of $86.1M and a last 12-month EBITDA of -$13.9M.
In the most recent fiscal year, NeuroPace achieved revenue of $79.9M and an EBITDA of -$16.6M.
NeuroPace expects next 12-month revenue of XXX and NTM EBITDA of XXX
See NeuroPace valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $86.1M | XXX | $79.9M | XXX | XXX | XXX |
| Gross Profit | $64.0M | XXX | $59.1M | XXX | XXX | XXX |
| Gross Margin | 74% | XXX | 74% | XXX | XXX | XXX |
| EBITDA | -$13.9M | XXX | -$16.6M | XXX | XXX | XXX |
| EBITDA Margin | -16% | XXX | -21% | XXX | XXX | XXX |
| EBIT | -$21.6M | XXX | -$21.7M | XXX | XXX | XXX |
| EBIT Margin | -25% | XXX | -27% | XXX | XXX | XXX |
| Net Profit | -$27.1M | XXX | -$27.1M | XXX | XXX | XXX |
| Net Margin | -32% | XXX | -34% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $46.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, NeuroPace's stock price is $13.
NeuroPace has current market cap of $434M, and EV of $440M.
See NeuroPace trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $440M | $434M | XXX | XXX | XXX | XXX | $-0.89 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, NeuroPace has market cap of $434M and EV of $440M.
NeuroPace's trades at 5.5x EV/Revenue multiple, and -26.6x EV/EBITDA.
Equity research analysts estimate NeuroPace's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
NeuroPace has a P/E ratio of -16.0x.
See valuation multiples for NeuroPace and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $434M | XXX | $434M | XXX | XXX | XXX |
| EV (current) | $440M | XXX | $440M | XXX | XXX | XXX |
| EV/Revenue | 5.1x | XXX | 5.5x | XXX | XXX | XXX |
| EV/EBITDA | -31.7x | XXX | -26.6x | XXX | XXX | XXX |
| EV/EBIT | -20.4x | XXX | -20.3x | XXX | XXX | XXX |
| EV/Gross Profit | 6.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -16.0x | XXX | -16.0x | XXX | XXX | XXX |
| EV/FCF | -24.3x | XXX | -24.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNeuroPace's last 12 month revenue growth is 15%
NeuroPace's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.4M for the same period.
NeuroPace's rule of 40 is -20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
NeuroPace's rule of X is 21% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for NeuroPace and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Margin | -16% | XXX | -21% | XXX | XXX | XXX |
| EBITDA Growth | -16% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -20% | XXX | -6% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 21% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 30% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 101% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
NeuroPace acquired XXX companies to date.
Last acquisition by NeuroPace was XXXXXXXX, XXXXX XXXXX XXXXXX . NeuroPace acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was NeuroPace founded? | NeuroPace was founded in 1997. |
| Where is NeuroPace headquartered? | NeuroPace is headquartered in United States of America. |
| How many employees does NeuroPace have? | As of today, NeuroPace has 184 employees. |
| Who is the CEO of NeuroPace? | NeuroPace's CEO is Mr. Joel Becker. |
| Is NeuroPace publicy listed? | Yes, NeuroPace is a public company listed on NAS. |
| What is the stock symbol of NeuroPace? | NeuroPace trades under NPCE ticker. |
| When did NeuroPace go public? | NeuroPace went public in 2021. |
| Who are competitors of NeuroPace? | Similar companies to NeuroPace include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of NeuroPace? | NeuroPace's current market cap is $434M |
| What is the current revenue of NeuroPace? | NeuroPace's last 12 months revenue is $86.1M. |
| What is the current revenue growth of NeuroPace? | NeuroPace revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of NeuroPace? | Current revenue multiple of NeuroPace is 5.1x. |
| Is NeuroPace profitable? | Yes, NeuroPace is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of NeuroPace? | NeuroPace's last 12 months EBITDA is -$13.9M. |
| What is NeuroPace's EBITDA margin? | NeuroPace's last 12 months EBITDA margin is -16%. |
| What is the current EV/EBITDA multiple of NeuroPace? | Current EBITDA multiple of NeuroPace is -31.7x. |
| What is the current FCF of NeuroPace? | NeuroPace's last 12 months FCF is -$18.1M. |
| What is NeuroPace's FCF margin? | NeuroPace's last 12 months FCF margin is -21%. |
| What is the current EV/FCF multiple of NeuroPace? | Current FCF multiple of NeuroPace is -24.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
